Anadys initiates dosing in Phase I hepatitis C study
ANA773 is the company’s investigational oral TLR7 agonist prodrug. In part B of the study, patients in the first cohort will receive 800mg of ANA773 every other day
Ionis Pharmaceuticals has entered a licence agreement granting global pharmaceutical company Recordati exclusive rights to develop and commercialise zilganersen to treat Alexander disease (AxD) in countries outside the US.